Sci header


Cellarity is developing new medicines that account for all aspects of illness, from the molecular level to the cell to the patient.


Modern drug discovery focuses on either molecular (target-based) or cellular (phenotypic) biology. Through either path, discovering new medicines to prevent or cure diseases in patients requires a series of linear translations across model systems spread over many years.

Cellarity’s approach is simultaneously molecular, cellular, phenotypic, organismal and clinical.

From this new vantage point, the platform reveals the molecular networks that drive disease in patients and identifies the appropriate, disease-relevant in vitro and in vivo model systems, reducing translational risk and time.

Cellarity Vantage Point v3 20191127

Fit-for-Purpose Medicine

On average, the human body contains approximately 30 trillion cells, each with a critical behavior. What if targeting cell behaviors were a better way of treating disease? Cellarity Maps™ make it possible to explore the cell behaviors that contribute to diverse diseases and guide identification of new medicines. Cellarity has identified nearly a dozen lead candidates, with in vivo proof-of-concept, in areas of significant unmet medical need.

Exploring Diverse Disease

Interact with the disease touchpoints to explore the types of questions Cellarity is asking.

Therapeutic Man Model

What if diseases of cell number aberrations could be treated by altering cell behaviors?

Diseases include: EPO Refractory Anemia, Thrombocythemia, Allergic Asthma

Group 90 Created with Sketch. Diseases include: EPO Refractory Anemia, Thrombocythemia, Allergic Asthma Diseases include: EPO Refractory Anemia, Thrombocythemia, Allergic Asthma

Cellarity has generated over 250 Cellarity Maps that aid our scientists to better explore and navigate different healthy and diseased cell populations. Cellarity Maps aid in testing clinical hypotheses to alter cell behavior using different therapeutic modalities.

Group 41 Copy Created with Sketch.